 Chronic viral hepatitis is common in dialysis patients, with the reported prevalence and annual incidence of 3-80 and 2.9, respectively. Currently, percutaneous liver biopsy PLB remains the gold standard for grading necroinflammation and staging fibrosis in patients with liver diseases. In addition, liver histology can help clinicians determine the eligibility of renal transplantation, prognosis, and necessity of antiviral therapy in dialysis patients with chronic viral hepatitis. In chronic hepatitis patients with normal renal function NRF, the risks of fatal and non-fatal hemorrhage after liver biopsies for non-malignant diseases were 0.04 and 0.16, respectively. However, the relative risks of post-biopsy hemorrhage in CHC patients with end-stage renal disease to those with NRF remain disputed. 